Snapshot from Jul 07, 2026 at 01:18 UTC. For live data and tracking: View Live
Entities / Companies / ChemoCentryx
Company

ChemoCentryx

Tracked across 1 events · 9 articles · First seen Jun 26, 2026 · Last active Jun 26, 2026

Sentiment
-50
Attention
4
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (1)
4 -50
Regulatory
EU Revokes TAVNEOS Marketing Authorization
Impact: ChemoCentryx developed TAVNEOS and is the NDA holder in the US. Although acquired by Amgen, the revocation of the EU marketing authorization for its developed drug is a negative development.
Jun 26, 2026 · 9 articles
ERGEN INTELLIGENCE
Track ChemoCentryx live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.